Vaccine Development

Apr 12, 2018
By BioPharm International Editors
The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.
Apr 01, 2018
BioPharm International
Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.
Mar 08, 2018
By BioPharm International Editors
GlobalData reports the need to shift away from egg-based manufacturing of vaccines in light of influenza-related deaths.
Feb 15, 2018
By BioPharm International Editors
Fluarix Tetra has been approved for use in children aged six months and above.
Jan 12, 2018
By BioPharm International Editors
An antibody-based Zika virus therapeutic that protected monkeys from infection might be safe enough for administration to pregnant women.
Jan 04, 2018
By BioPharm International Editors
The companies will collaborate on the development of vaccines to expand GeoVax’s cancer immunotherapy program.
Dec 14, 2017
By BioPharm International Editors
Children with a rare brainstem-based cancer might be helped by a new immunotherapy that targets a mutated protein found exclusively in cancer cells.
Nov 15, 2017
BioPharm International
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
Nov 15, 2017
BioPharm International
Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.
Nov 15, 2017
BioPharm International
Alternatives to time-consuming, error-prone operations promise to reduce vaccine manufacturing costs and improve facility flexibility.
native1_300x100
lorem ipsum